NasdaqGS - Nasdaq Real Time Price USD

Atara Biotherapeutics, Inc. (ATRA)

6.84
-0.77
(-10.12%)
At close: May 16 at 4:00:02 PM EDT
6.85
+0.01
+(0.15%)
Pre-Market: 8:31:05 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
128,940
128,940
8,573
63,573
20,340
Cost of Revenue
21,009
21,009
8,886
0
--
Gross Profit
107,931
107,931
-313
63,573
--
Operating Expense
191,369
191,369
275,693
344,086
360,802
Operating Income
-83,438
-83,438
-276,006
-280,513
-340,462
Net Non Operating Interest Income Expense
-2,505
-2,505
141
2,686
367
Other Income Expense
528
528
-246
49,537
--
Pretax Income
-85,415
-85,415
-276,111
-228,290
-340,095
Tax Provision
-12
-12
15
12
46
Net Income Common Stockholders
-85,403
-85,403
-276,126
-228,302
-340,141
Diluted NI Available to Com Stockholders
-85,403
-85,403
-276,126
-228,302
-340,141
Basic EPS
-25.32
-11.41
-65.19
-56.00
-90.75
Diluted EPS
-25.32
-11.41
-65.19
-56.00
-90.75
Basic Average Shares
5,891.73
7,488
4,236
4,079.60
3,746.80
Diluted Average Shares
5,891.73
7,488
4,236
4,079.60
3,746.80
Total Operating Income as Reported
-83,438
-83,438
-276,006
-280,513
-340,462
Total Expenses
212,378
212,378
284,579
344,086
360,802
Net Income from Continuing & Discontinued Operation
-85,403
-85,403
-276,126
-228,302
-340,141
Normalized Income
-85,403
-85,403
-276,126
-278,539
-340,141
Interest Income
2,110
2,110
5,426
3,059
367
Interest Expense
4,615
4,615
5,285
373
--
Net Interest Income
-2,505
-2,505
141
2,686
367
EBIT
-80,800
-80,800
-270,826
-227,917
-340,462
EBITDA
-75,749
-75,749
-265,997
-222,264
-331,117
Reconciled Cost of Revenue
21,009
21,009
8,886
0
--
Reconciled Depreciation
5,051
5,051
4,829
5,653
9,345
Net Income from Continuing Operation Net Minority Interest
-85,403
-85,403
-276,126
-228,302
-340,141
Total Unusual Items Excluding Goodwill
--
--
0
50,237
0
Total Unusual Items
--
--
0
50,237
0
Normalized EBITDA
-75,749
-75,749
-265,997
-272,501
-331,117
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 10/16/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MIST Milestone Pharmaceuticals Inc.
1.2200
+6.09%
 
ABEO Abeona Therapeutics Inc.
6.10
+5.35%
 
KPTI Karyopharm Therapeutics Inc.
5.32
-2.21%
 
RGNX REGENXBIO Inc.
8.89
+2.89%
 
ALLO Allogene Therapeutics, Inc.
1.1100
+1.83%
 
CHRS Coherus BioSciences, Inc.
0.7610
-0.91%
 
MGNX MacroGenics, Inc.
1.5800
+2.60%
 
VSTM Verastem, Inc.
7.59
-4.29%
 
ITOS iTeos Therapeutics, Inc.
7.81
-2.01%
 
CAPR Capricor Therapeutics, Inc.
9.44
-1.26%